Orion Oyj Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Aino Anna Liisa Hurme
- Full Time Employees
- 4,029
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Orionintie 1A Espoo UU Finland 02200
- IPO Date
- Jul 3, 2006
- Website
- orionpharma.com
- Similar Companies
- Business
- Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals along with active pharmaceutical ingredients (APIs). Its product portfolio comprises patented prescription drugs focused on neurological disorders, oncology, respiratory diseases, cardiovascular diseases, hormonal and urological conditions; generic, over-the-counter (OTC), and biosimilar medicines; veterinary medicines and animal well-being products; and pharmaceutical ingredients and contract manufacturing services. Flagship products include Nubeqa for prostate cancer, Easyhaler inhalation products, Stalevo and Comtess/Comtan for Parkinson's disease, Simdax for acute decompensated heart failure, and sedatives such as Precedex and Dexdor. The company also offers veterinary drugs such as Bonqat, Clevor, Domosedan, and Sileo. Orion operates primarily in Finland, Scandinavia, other parts of Europe, North America, and globally, with most manufacturing and R&D facilities located in Finland. Founded in 1917, Orion is headquartered in Espoo, Finland. In recent developments, Orion has achieved significant sales growth driven by the blockbuster performance of Nubeqa, which surpassed EUR 1 billion in sales in 2024. The company saw a 35.3% year-over-year increase in net sales in Q4 2024 and overall strong financial results with rising operating profits. Orion is investing in capacity expansion, particularly for Easyhaler products and the Nubeqa production line at its Fermion site in Hanko, Finland. Strategic alliances include a discovery service and commercial license agreement with Invenra for bispecific antibody cancer therapeutics and collaboration with Abilita Therapeutics for innovative antibody therapeutics. Orion also leverages artificial intelligence technologies for drug innovation. The company recently secured a EUR 180 million milestone payment related to Nubeqa sales and maintains a positive outlook for continued growth in 2025. Orion’s business segments comprise prescription pharmaceuticals, self-care products, veterinary pharmaceuticals, and contract manufacturing services. Its target markets include specialist and general practitioners, hospitals, pharmacies, veterinarians, healthcare centers, and clinics. Orion’s comprehensive focus covers therapeutic areas such as oncology, neurology, respiratory diseases, cardiovascular diseases, and animal health. The company’s longstanding presence and strategic innovation activities position it as a leading pharmaceutical group in the Nordic region and a competitive global player in specialty human and veterinary medicines.
Company News
Orion OYJ (OTCMKTS:ORINY) & Sonoma Pharmaceuticals (NASDAQ:SNOA) Head to Head Contrast
Orion OYJ (OTCMKTS:ORINY) Shares Gap Down – Here’s What Happened
Financial Analysis: Orion OYJ (OTCMKTS:ORINY) versus Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)
Orion OYJ (OTCMKTS:ORINY) Hits New 52-Week High – Time to Buy?
Orion Oyj (ORINF) Q2 2026 Earnings Call Transcript
Orion Oyj (ORINF) Q1 2026 Earnings Call Transcript
Orion Oyj (ORINF) Q4 2025 Earnings Call Transcript
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Oyj (ORINF) Q3 2025 Earnings Call Transcript
What Makes Orion OYJ (ORINY) a Good Fit for 'Trend Investing'
5 Stocks With Recent Price Strength to Maximize Your Gains
Here is Why Growth Investors Should Buy Orion OYJ (ORINY) Now
Orion OYJ (ORINY) is on the Move, Here's Why the Trend Could be Sustainable
Orion Oyj (ORINF) Q2 2025 Earnings Call Transcript
Looking for a Growth Stock? 3 Reasons Why Orion OYJ (ORINY) is a Solid Choice
Recent Price Trend in Orion OYJ (ORINY) is Your Friend, Here's Why
ORION Holdings Corp. (ORINF) Q1 2025 Earnings Call Transcript
ORION Holdings Corp. (ORINF) Q3 2024 Earnings Call Transcript
Orion OYJ (ORINY) Is a Great Choice for 'Trend' Investors, Here's Why
Is Orion OYJ (ORINY) a Solid Growth Stock? 3 Reasons to Think "Yes"